CHANGE IN CONTROL AND SEVERANCE AGREEMENTRelease Agreement • May 8th, 2023 • Fibrogen Inc • Pharmaceutical preparations • California
This Change in Control and Severance Agreement (this “Agreement”) is dated as of __________, 20__ (the “Effective Date”), by and between [______________] (“Executive”) and FibroGen, Inc., a Delaware corporation (the “Company”). This Agreement is intended to provide Executive with certain benefits described herein upon the occurrence of specific events.
AMENDMENT NO. 1 TO COMMERCIAL SUPPLY AGREEMENT (Roxadustat)Supply Agreement • May 8th, 2023 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 1 to the Commercial Supply Agreement (the “Agreement”) dated January 1, 2020 (“Effective Date”), is made and entered into as of January 1, 2023 (“Amendment No. 1 Effective Date”) by and between FibroGen, Inc. and its Affiliates (collectively, “FibroGen”), with offices located at 409 Illinois Street, San Francisco, California 94158, and Catalent Pharma Solutions, LLC (“Catalent”), a Delaware limited liability corporation, having an address at 14 Schoolhouse Road, Somerset, New Jersey 08873. FibroGen and Catalent may be referred to individually as a “Party”, and collectively as the “Parties”.
